Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965973 | 0.91 | — | — | |
| SCHEMBL19334293 | 0.89 | BRD4 (0.42) | BRD4TP53CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL14712106 | 0.87 | TP53 (0.52) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL7853872 | 0.87 | TP53 (0.52) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL14711275 | 0.87 | TP53 (0.52) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL16718949 | 0.84 | SMN1; SMN2 (0.50) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL10049180 | 0.84 | SMN1; SMN2 (0.50) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL35889 | 0.84 | SMN1; SMN2 (0.50) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL10049540 | 0.84 | SMN1; SMN2 (0.50) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL18434254 | 0.82 | SMN1; SMN2 (0.53) | BRD4TP53ALDH1A1SMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068774-B1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2019-12-25 | — | — | EP | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | BRD4 1225/4885TP53 1049/4885CHRNB2 4061/4885 |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | BRD4 1225/4885TP53 1049/4885CHRNB2 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.